Adjuvant Systemic Chemotherapy for Stage II and III Colon Cancer after Complete Resection: An Updated Practice Guideline

Clinical Oncology

Volumn 23, Issue 5, 2011, Pages 314-322

  Jonker, D J ^a   Spithoff, K ^b   Maroun, J ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Adjuvant therapy; Chemotherapy; Colonic neoplasms; Colorectal neoplasms; Practice guideline

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; TEGAFUR; URACIL;

ALOPECIA; ARTICLE; CANADA; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; COLON CANCER; COLON RESECTION; CONSENSUS DEVELOPMENT; DIARRHEA; DISEASE FREE SURVIVAL; EVIDENCE BASED PRACTICE; HEALTH SURVEY; HUMAN; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; HUMANS; NEOPLASM STAGING; ONTARIO;

EID: 79955675614     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2011.02.010     Document Type: Article

References (37)

1. National Cancer Institute of Canada Canadian cancer statistics 2010 2010, National Cancer Institute of Canada, Toronto.
2. Nauta R., Stablein D.M., Holyoke E.D. Survival of patients with stage B2 colon carcinoma. The Gastrointestinal Tumor Study Group experience. Arch Surg 1989, 124:180-182.
3. NIH Consensus Conference Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990, 264:1444-1450.
4. Figueredo A., Germond C., Maroun J., et al. Adjuvant therapy for stage II colon cancer after complete resection. Cancer Prev Control 1997, 1(5):379-392.
5. Figueredo A., Fine S., Maroun J., Walker-Dilks C., Wong S., the Provincial Gastrointestinal Disease Site Group Adjuvant therapy for stage III colon cancer after complete resection. Cancer Prev Control 1997, 1:304-319.
6. Figueredo A., Charette M.L., Maroun J., Brouwers M.C., Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Gastrointestinal Cancer Disease Site Group. J Clin Oncol 2004, 22(16):3395-3407.
7. Benson A.B., Schrag D., Somerfield M.R., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004, 22(16):3408-3419.
8. Haller D.G., Catalano P.J., MacDonald J.S., et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of intergroup 0089. J Clin Oncol 2005, 23:8671-8678.
9. Scheithauer W., Kornek G.V., Marczell A., et al. Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma. Br J Cancer 1998, 77:1349-1354.
10. Wolmark N., Rockette H., Mamounas E., et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin and levamisole in patients with Dukes' B and C carcinoma of the colon: results from the National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999, 17:3553-3559.
11. QUASAR Collaborative Group Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 2000, 355:1588-1596.
12. Porschen R., Bermann A., Loffler T., et al. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol 2001, 19:1787-1794.
13. Peretz T.H., Nissan A., Shani A., et al. Final results of a prospective randomized trial comparing 5-fluorouracil with levamisole to 5-fluorouracil with leucovorin as adjuvant therapy of colorectal - the Israel Cooperative Oncology Group (ICOG) study. Proc Am Soc Clin Oncol 2002, 21. abstract 2261.
14. Sargent D.J., Wieand H.S., Haller D.G., et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005, 23:8664-8670.
15. Sargent D.J., Adjuvant Colon Cancer Endpoints (ACCENT) Group Endpoints for colon adjuvant clinical trials (CACT): recommendations based on individual patient data (IPD) from 20898 patients (pts) and 18 randomized trials. J Clin Oncol 2005, 23(16S):3512.
16. Jonker D, Spithoff K, Maroun J, and the Gastrointestinal Cancer Disease Site Group. Adjuvant systemic chemotherapy for stage II and III colon cancer following complete resection. Available at: [cited 24 02 2011]. http://www.cancercare.on.ca/common/pages/userfile.aspx%3ffileid%3d14002.
17. Browman G.P., Levine M.N., Mohide E.A., et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995, 13:502-512.
18. Schippinger W., Samonigg H., Schaberl-Moser R., et al. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer 2007, 97:1021-1027.
19. QUASAR Collaborative Group Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007, 370:2020-2029.
20. Kuebler J.P., Colangelo L., O'Connell M.J., et al. Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin. Cancer 2007, 110:1945-1950.
21. Laffer U., Metzger U., Aeberhard P., et al. Adjuvant perioperative portal vein or peripheral intravenous chemotherapy for potentially curative colorectal cancer: long-term results of a randomized controlled trial. Int J Colorectal Dis 2008, 23:1233-1241.
22. Van Cutsem E., Labianca R., Bodoky G., et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009, 27:3117-3125.
23. Dahl O., Fluge O., Carlsen E., et al. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncologica 2009, 48:368-376.
24. Ychou M., Raoul J.L., Douillard J.Y., et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 2009, 20:674-680.
25. Andre T., Boni C., Navarro M., et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009, 27:3109-3116.
26. Figueredo A., Coombes M.E., Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer 2008, Cochrane Database of Systematic Reviews, Issue 3: doi: 10.1002/14651858.CD005390.pub2.
27. Twelves C., Wong A., Nowacki M.P., et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005, 352:2696-2704.
28. Twelves C., Wong A., Nowacki M., et al. Updated efficacy findings from the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes' C colon cancer. J Clin Oncol 2005, 23(16S):3521.
29. Scheithauer W., McKendrick J., Begbie S., et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003, 14:1735-1743.
30. Lembersky B.C., Wieand H.S., Petrelli N.J., et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project protocol C-06. J Clin Oncol 2006, 24:2059-2064.
31. Kopec J.A., Yothers G., Ganz P.A., et al. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol 2007, 25:424-430.
32. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351.
33. de Gramont A., Boni C., Navarro M., et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. J Clin Oncol 2007, 25(18S):4007.
34. Kuebler J.P., Wieand H.S., O'Connell M.J., et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007, 25:2198-2204.
35. Land S.R., Kopec J.A., Cecchini R.S., et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007, 25:2205-2211.
36. Saltz L.B., Niedzwiecki D., Hollis D., et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007, 25:3456-3461.
37. Sasaki K., Takasaka H., Kiriyama K., et al. Adjuvant postoperative chemotherapy for Dukes C colorectal cancer; weekly low-dose irinotecan (CPT-11) plus oral 5-FU versus oral 5-FU only. J Clin Oncol 2004, 22(14S):3735.